Table 1.
Selected agents targeting amino acid metabolism for cancer treatment.
| Target | Treatment | Stage | Cancer Type | Reference(s) | |
|---|---|---|---|---|---|
| Glutamine | GLS1 | CB-839+cabozantinib | Phase II | Renal cell carcinoma | NCT03428217 |
| CB-839 + talazoparib | Phase Ib/II | Solid tumors | NCT03875313 | ||
| CB-839 + paclitaxel | Phase II | TNBC | NCT03057600 | ||
| CB-839 hydrochloride + sapanisertib | Phase I/Ib | NSCLC | NCT04250545 | ||
| CB-839 + Panitumumab and Irinotecan | Phase I/II | Metastatic and refractory RAS wildtype colorectal | NCT03263429 | ||
| CB-839 + Azacitidine | Phase I/II | Advanced myelodysplastic syndrome | NCT03047993 | ||
| CB-839 + capecitabine | Phase I/II | Advanced solid tumors, colorectal cancer | NCT02861300 | ||
| ACB-839 + palbociclib | Phase Ib/II | Solid tumors | NCT03965845 | ||
| ASCT2 | V-9302 | Preclinical | In vivo mouse models and in vitro | [52, 105, 113, 114] | |
| Cysteine | xCT | Sorafenib | In clinic | Kidney, liver, and thyroid cancer | 207012 |
| PRLX 93936 (erastin analog) | Phase I | Solid tumors | NCT00528047 | ||
| Serine | PHGDH | NCT-502 | Preclinical | In vitro | [107, 115] |
| NCT-503 | Preclinical | In vitro and mouse | [107] | ||
| Arginine | Arginine auxotrophic cancer cells | ADI-PEG-20 | Phase II | Metastatic Melanoma | NCT00450372 |
| ADI-PEG 20 | Phase II | Non-Hodgkin’s Lymphoma | NCT01910025 | ||
| ADI-PEG 20 | Phase I | Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors | NCT01665183 | ||
| ADI-PEG 20 | Phase II | Acute Myeloid Leukemia | NCT01910012 | ||
| ADI-PEG 20 | Phase I | HER2 Negative Metastatic Breast Cancer | NCT01948843 |